Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Certara Inc (CERT) USD0.01

Sell:$34.88 Buy:$35.01 Change: $0.73 (2.06%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.73 (2.06%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.73 (2.06%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Certara, Inc. offers biosimulation software and technology. The Company develops medicines to patients using biosimulation software and technology for drug discovery and development. Biosimulation is a technology used to conduct virtual trials by using virtual patients to predict how drugs behave in different individuals. The Company delivers software products and technology-enabled services to customers to carry out biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. The Company’s regulatory science and market access software and services are supported by technologies including regulatory submissions software, natural language processing and Bayesian analytics. The Company has operations in the United States, Canada, Spain, Luxembourg, Portugal, United Kingdom, Germany, France, Netherlands, Denmark, Switzerland, Italy, Poland, Japan, Philippines, India, and Australia.

Contact details

100 Overlook Center, Suite 101
United States
+1 (609) 7167900

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$5.46 billion
Shares in issue:
157.36 million
Health Care Technology
United States
US dollar

Key personnel

  • William Feehery
    Chief Executive Officer, Director
  • M. Andrew Schemick
    Chief Financial Officer
  • Robert Aspbury
    President - Simcyp
  • Justin Edge
    President - Regulatory and Access
  • Leif Pedersen
    President - Software
  • Craig Rayner
    President - Integrated Drug Development and Strategic Consulting Services
  • Judith Dickinson
    Chief Human Resource Officer, Senior Vice President - Human Resources
  • Richard Traynor
    Senior Vice President , General Counsel
  • Jieun Choe
    Chief Strategy and Marketing Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.